Trexquant Investment LP Invests $6.50 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Trexquant Investment LP purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 67,433 shares of the biotechnology company's stock, valued at approximately $6,503,000. Trexquant Investment LP owned about 0.07% of Sarepta Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Sarepta Therapeutics by 0.5% in the third quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company's stock worth $1,039,212,000 after acquiring an additional 41,465 shares during the last quarter. Picton Mahoney Asset Management purchased a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at $2,576,000. WCM Investment Management LLC purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter valued at $600,000. Capula Management Ltd acquired a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth $1,409,000. Finally, State of New Jersey Common Pension Fund D raised its position in shares of Sarepta Therapeutics by 8.2% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 51,398 shares of the biotechnology company's stock worth $4,956,000 after buying an additional 3,912 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SRPT shares. Evercore ISI upped their price target on Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an "in-line" rating in a research note on Tuesday, February 20th. Oppenheimer raised shares of Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and set a $180.00 target price for the company in a research report on Tuesday, May 14th. Wedbush reaffirmed an "outperform" rating and set a $224.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Citigroup increased their price objective on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a "buy" rating in a research report on Thursday, February 29th. Finally, TheStreet upgraded shares of Sarepta Therapeutics from a "d" rating to a "c-" rating in a report on Monday, March 4th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $163.94.

Insider Activity

In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the transaction, the insider now owns 26,836 shares of the company's stock, valued at approximately $3,457,550.24. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Stephen Mayo sold 3,135 shares of the business's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total transaction of $385,479.60. Following the completion of the sale, the director now owns 6,621 shares of the company's stock, valued at approximately $814,118.16. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Bilal Arif sold 2,000 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the sale, the insider now owns 26,836 shares in the company, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,731 shares of company stock worth $3,248,319. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Stock Down 0.6 %

SRPT stock traded down $0.82 during midday trading on Wednesday, hitting $128.30. 723,254 shares of the company's stock were exchanged, compared to its average volume of 1,016,977. The firm has a 50 day moving average price of $126.83 and a 200-day moving average price of $113.60. Sarepta Therapeutics, Inc. has a 12-month low of $55.25 and a 12-month high of $150.16. The stock has a market capitalization of $12.13 billion, a price-to-earnings ratio of 1,166.36 and a beta of 0.95. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The business had revenue of $413.50 million during the quarter, compared to analyst estimates of $375.52 million. During the same quarter in the previous year, the firm earned ($1.44) earnings per share. The business's revenue was up 63.1% compared to the same quarter last year. On average, analysts anticipate that Sarepta Therapeutics, Inc. will post 2.68 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.